In comparison to wild-type FLT3 AML, FLT3m AML is associated with an increased risk of relapse and inferior survival (OS), particularly in patients without concomitant NPM1 mutation [2,3]. The gene discussed is NPM1; the disease is acute myeloid leukemia.